Dyadic International (DYAI) IAccess Alpha Virtual MicroCap Conference summary

Strategic direction and business model

• Transitioned from R&D and grant-based revenues to commercial execution, focusing on scalable, animal-free recombinant protein solutions for life sciences, food nutrition, and bio-industrial markets.

• Employs dual microbial platforms (C1 and Dapibus) to address different market segments, emphasizing speed, productivity, and cost efficiency.

• Monetization strategy is based on 'buy, brand, and build'—direct sales, licensing, and enabling partners to build their own brands using the technology.

• Focused on non-therapeutic products to enable faster commercialization and near-term revenue, with regulatory pathways that avoid lengthy FDA reviews.

• Rebranded as Dyadic Applied Biosolutions, aligning all materials and strategy with commercial goals.

Product portfolio and market focus

• Life sciences: Launching cell culture media components (albumin, transferrin, growth factors), molecular biology reagents (DNase I), and leveraging partnerships for global distribution.

• Food nutrition: Targeting non-animal dairy proteins (bovine/human alpha-lactalbumin, lactoferrin), with partnerships for commercialization and applications in infant and sports nutrition.

• Bio-industrial: Re-entered via partnership with Fermbox Bio, focusing on cellulosic enzymes for biofuels and biomass conversion, with initial purchase orders and expected revenues in early 2026.

• Multiple products are being layered across segments, with direct sales, OEM, and licensing channels.

• Expanding into cosmetics and other applications, leveraging platform flexibility.

Commercialization and partnerships

• Active partnerships with Proliant (albumin), Brig Bio (bovine alpha-lactalbumin), Enzymes (non-animal dairy enzyme), and Fermbox Bio (bio-industrial enzymes), each providing milestone payments, royalties, and co-marketing opportunities.

• Intralink partnership expands reach in Asia-Pacific, targeting rapidly growing cell and gene therapy markets.

• Externally funded legacy R&D programs (Gates Foundation, CEPI) continue to provide validation and visibility without diverting resources from commercial focus.

• Customer pipeline spans cell culture media, non-animal dairy, and industrial applications, with multiple distribution and supply agreements in place.

• Partnerships enable rapid entry into new markets and supplement internal expertise.